AZD2066
- Generic Name
- AZD2066
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16ClN5O2
- CAS Number
- 934282-55-0
- Unique Ingredient Identifier
- MQ908Y1ZB2
- Associated Conditions
- -
- Associated Therapies
- -
6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2012-10-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 131
- Registration Number
- NCT01145755
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
AZD2066 Neuropathic Pain - Mechanical Hypersensitivity
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2012-09-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 87
- Registration Number
- NCT00939094
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
AZD2066 Cocktail Study
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2009-10-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT00930306
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2012-11-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 127
- Registration Number
- NCT00857623
- Locations
- 🇺🇸
Reasearch Site, Albany, New York, United States
🇺🇸Reserach Site, Bella Vista, Arkansas, United States
🇺🇸Research Site, San Antonio, Texas, United States
Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066
Phase 1
Completed
- Conditions
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2009-02-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT00829088
- Locations
- 🇬🇧
Research Site, Cheshire, United Kingdom
14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2010-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00813306
- Locations
- 🇳🇱
Research site, Amsterdam, Netherlands
Study to Assess the Safety, Tolerability and Pharmacokinetics After Multiple Doses of AZD2066 in Japanese Subjects
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2009-08-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 132
- Registration Number
- NCT00766012
- Locations
- 🇯🇵
Research SIte, Fukuoka, Japan
AZD 2066 Single Dose Formulation and Food Effect Study in Healthy Volunteers
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT00690404
Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066
Phase 1
Completed
- Conditions
- First Posted Date
- 2008-05-29
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT00686504
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 110
- Registration Number
- NCT00684502
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath